Skye Bioscience (SKYE) Interest Expenses (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Interest Expenses of $2199.0 for Q1 2026, up 51.45% year-over-year from $1452.0 in Q1 2025, and down 99.87% quarter-over-quarter from $1.7 million in Q3 2025.
Skye Bioscience (SKYE) Interest Expenses (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Interest Expenses for 15 consecutive years, with $2199.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 51.45% year-over-year to $2199.0; the TTM figure through Mar 2026 stood at -$359235.0 (up 50.79% YoY), while the FY2024 annual figure was $67.7 million, up 1.93% from the prior year.
- Interest Expenses retreated to $2199.0 in Q1 2026 per SKYE's latest filing, from $1.7 million in the prior quarter.
- Across five years, Interest Expenses topped out at $5.7 million in Q1 2024 and bottomed at -$362886.0 in Q4 2024.
- Historically, Interest Expenses has averaged $753470.2 across 5 years, with a median of $202166.5 in 2022.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 142.03% — and 2024, when it surged 30769.09%.
- Skye Bioscience's Interest Expenses stood at $660858.0 in 2022, then slumped by 142.03% to -$277783.0 in 2023, then slumped by 30.64% to -$362886.0 in 2024, then surged by 580.16% to $1.7 million in 2025, then plunged by 99.87% to $2199.0 in 2026.
- Business Quant data shows SKYE's Interest Expenses at $2199.0 in Q1 2026, $1.7 million in Q3 2025, and $2.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 93.62 Mn |
| 10 | Skye Bioscience | 10.64 Mn | 10.64 Mn | - | 3,299.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,199.00 |
| Mar 31, 2026 | 2,199.00 |
| Sep 30, 2025 | 1.74 Mn |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 1,452.00 |
| Mar 31, 2025 | 1,452.00 |
| Dec 31, 2024 | -362,886.00 |
| Dec 31, 2024 | -362,886.00 |
| Sep 30, 2024 | -90,766.00 |
| Sep 30, 2024 | -90,766.00 |
| Jun 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 5.68 Mn |
| Mar 31, 2024 | 5.68 Mn |
| Dec 31, 2023 | -277,783.00 |
| Dec 31, 2023 | -277,783.00 |
| Sep 30, 2023 | 271,307.00 |
| Sep 30, 2023 | 271,307.00 |